You are here:
- Office Overview
- Section of inflammation of Cardiometabolic Diseases
- Translational Genetics and Genomics Unit
Section of inflammation of Cardiometabolic Diseases
Dr. Rose came to the National Institutes of Health (NIH) in 2013 as part of the Metzger Clinical Scholars Program. He is dually appointed at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Heart, Lung and Blood Institute (NHLBI). Dr. Rose has received numerous local and national awards and honors. He also is actively involved in several organizations in membership and leadership roles, including the American College of Rheumatology and Group for the Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
The central focus of Dr. Rose’s research program is to examine the effects of systemic inflammation on the development of cardiovascular and metabolic disease. Psoriasis and psoriatic arthritis, two related chronic inflammatory conditions, are studied to understand the impact of these disorders on obesity, insulin resistance, lipoprotein dysfunction, and vascular disease. A multi-faceted approach is taken to explore these relationships at the clinical, translational, and basic level. At the clinical level, various disease features are related to tissue-specific inflammation, which is identified using novel imaging modalities including PET/CT (Figure 1) and PET/MRI. At the translational level, blood and tissue specimens undergo extensive cellular and molecular characterization to understand how the innate and adaptive immune systems alter adipose tissue phenotype and function. At the basic level, animal models of psoriasis- and psoriatic arthritis-like disease are utilized to explore the role of immune cells and their pleiotropic receptors in driving metabolic inflammation. The ultimate goal of these studies is to uncover novel mechanisms linking systemic inflammation and vascular and metabolic dysfunction as a gateway to future clinical trials.
Figure 1: FDG-PET/CT imaging of the vasculature reveals inflammation in the proximal aorta of a patient with psoriasis (inflamed) compared to a healthy control (unaffected).
Dr. Rose first became interested in the link between systemic inflammation and cardiometabolic disease while developing the first animal model of inflammatory arthritis that was also susceptible to dyslipidemia and atherosclerosis. His prior work sparked a clinical interest in the field, as patients with rheumatic diseases are more susceptible to metabolic and vascular disease, which leads to increased morbidity and mortality in this patient population. Dr. Rose came to the NIH to be an associate investigator in the Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI) at the NHLBI. As part of this large longitudinal study, Dr. Rose performs rheumatologic evaluations at the NIH Clinical Center for patients with psoriasis and psoriatic arthritis. He also performs internal medicine evaluations for a comparator population of healthy participants and patients with coronary artery disease and diabetes mellitus. During these assessments, blood, skin, and adipose tissue samples are obtained. This approach allows for powerful comparisons of cellular and molecular phenotypes across various disease states. Cellular and molecular markers are then related to clinical and multi-modal imaging parameters. The ultimate goal of these studies will be to identify new therapeutic avenues to treat both systemic inflammation and its metabolic and vascular complications in the rheumatic diseases.
Nowak M, Carrasquillo JA, Yarboro CH, Bacharach SL, Whatley M, Valencia X, Takada K, Brust DG, Illei GG. A pilot study of the use of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus. Arthritis Rheum. 2004; 50(4): 1233-8.
Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002; 46(4): 995-1002.
Evans JT, Cravens P, Gatlin J, Kelly PF, Lipsky PE, Garcia JV. Pre-clinical evaluation of an in vitro selection protocol for the enrichment of transduced CD34+ cell-derived human dendritic cells. Gene Ther. 2001 Sep; 8(18): 1427-35.See extended list of publications
Updated May 22, 2014